Joseph Frattaroli
Plus aucun poste en cours
Fortune : 17 312 $ au 31/03/2024
Profil
Joseph Frattaroli is the founder of Flagship Consulting, Inc. (founded in 2010).
He was the President, Chief Executive & Financial Officer at Vaso Active Pharmaceuticals, Inc. from 2009 to 2012.
He is currently the Chief Financial Officer at Inhibikase Therapeutics, Inc. (2018-2024).
Mr. Frattaroli obtained his undergraduate degree from Salem State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 8 015 ( 0,13% ) | 17 312 $ | 31/03/2024 |
Anciens postes connus de Joseph Frattaroli
| Sociétés | Poste | Fin |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2024 |
Vaso Active Pharmaceuticals, Inc.
 Vaso Active Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vaso Active Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The Company focuses on vaso active lipid encapsulated or VALE, transdermal delivery technology drugs. Currently, they market Athlete's Relief and Osteon in the United States. The Company's products, include Analgesics, Toenail fungal treatment, Acne, First aid, Hand and body lotion and Psoriasis treatment. It is planning to rebrand the deFEET athlete's foot anti-fungal medication product as Termin8 and Xtinguish. | Director of Finance/CFO | 06/11/2012 |
| Flagship Consulting, Inc. | Founder | - |
Formation de Joseph Frattaroli
| Salem State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Vaso Active Pharmaceuticals, Inc.
Vaso Active Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vaso Active Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The Company focuses on vaso active lipid encapsulated or VALE, transdermal delivery technology drugs. Currently, they market Athlete's Relief and Osteon in the United States. The Company's products, include Analgesics, Toenail fungal treatment, Acne, First aid, Hand and body lotion and Psoriasis treatment. It is planning to rebrand the deFEET athlete's foot anti-fungal medication product as Termin8 and Xtinguish. | Health Technology |
| Flagship Consulting, Inc. |
